Synapse - Andrew Zelenetz

Search Within

Andrew D Zelenetz

Results (785)

Pralatrexate (PDX) produces a high and durable complete response rate in patients with chemotherapy resistant T-cell lymphomas

Meeting Abstract

O'Connor, O. A.; Hamlin, P.; Moskowitz, C.; Portlock, C.; Sarasohn, D.; Dumitrescu, O.; Neylon, E.; Patterson, M.; Zelenetz, A.; Saunders, M.; more...
Annals of Oncology (2008)

Fulltext@MSK | Save

Normalization of FDG-PET pre-ASCT with additional non-cross resistant chemotherapy improves EFS in patients with relapsed and primary refractory Hodgkin lymphoma - Memorial Sloan Kettering protocol 04-047

Meeting Abstract

Moskowitz, C. H.; Nimer, S. D.; Zelenetz, A. D.; Hamlin, P. A.; Horwitz, S. M.; Noy, A.; Portlock, C. S.; Straus, D. J.; Gerecitano, J.; Kewalramani, T.; more...
Blood (2008)

Fulltext@MSK | Save

Pre-transplant evaluation with both CT and PET following second-line therapy is essential for predicting outcome in patients with transplant-eligible relapsed and primary refractory Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Nimer, S. D.; Zelenetz, A. D.; Kewalramani, T.; Vanak, J. M.; Maragulia, J. C.; Yahalom, J.; Moskowitz, C.
Blood (2008)

Fulltext@MSK | Save

Clofarabine is active in peripheral T-cell lymphomas: Results of the phase I portion of a phase I/II study

Meeting Abstract

Horwitz, S.; Mulford, D.; Paul, H.; Weissbrot, H.; Zelenetz, A. D.
Annals of Oncology (2008)

Fulltext@MSK | Save

Influence of post-second-line chemotherapy PET Imaging and involved field radiotherapy prior to high dose therapy on outcomes of relapsed or refractory diffuse large B cell lymphoma

Meeting Abstract

Hoppe, B. S.; Moskowitz, C. H.; Zhang, Z.; Kewalramani, T.; Maragulia, J. C.; Rice, R. D.; Reiner, A. S.; Hamlin, P. A.; Zelenetz, A. D.; Yahalom, J.
International Journal of Radiation Oncology, Biology, Physics (2008)

Fulltext@MSK | Save

Bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P): Two dosing schedules of a novel phase I regimen in patients with relapsed/refractory indolent and mantle cell lymphomas

Meeting Abstract

Gerecitano, J.; Portlock, C.; Hamlin, P.; Moskowitz, C.; Noy, A.; Straus, D.; Zelenetz, A. D.; Schulman, P.; Dumitrescu, O.; O'Connor, O. A.
Annals of Oncology (2008)

Fulltext@MSK | Save

Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network

Journal Article

LaCasce, A. S.; Kho, M. E.; Friedberg, J. W.; Niland, J. C.; Abel, G. A.; Rodriguez, M. A.; Czuczman, M. S.; Millenson, M. M.; Zelenetz, A. D.; Weeks, J. C.
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

Treatment of follicular lymphoma: Current status

Journal Article

Tilly, H.; Zelenetz, A.
Leukemia and Lymphoma (2008)

Fulltext@MSK | Save

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

Journal Article

O'Connor, O. A.; Portlock, C.; Moskowitz, C.; Straus, D.; Hamlin, P.; Stubblefield, M.; Dumitrescu, O.; Colevas, A. D.; Grant, B.; Zelenetz, A.
British Journal of Haematology (2008)

Fulltext@MSK | Save

Overview of lymphoma diagnosis and management

Journal Article

Matasar, M. J.; Zelenetz, A. D.
Radiologic Clinics of North America (2008)

Fulltext@MSK | Save